Biogen

Anonymous board for Biogen
Post thread


Call backs?
Replies
34
Views
7K
anonymous
STAT: The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab
Replies
1
Views
1K
anonymous
Executive nominated to board is directors baby mama
Replies
6
Views
4K
anonymous
Hiring event
Replies
8
Views
3K
anonymous
CNBC: Sanders condemns Alzheimer's treatment price, calls for HHS action
Replies
9
Views
1K
anonymous
IT Moving to India
Replies
5
Views
2K
anonymous
Biosimilar for Lucentis approved
Replies
33
Views
11K
PapaWhisky
Bloomberg: Biogen Defends Alzheimer’s Drug Trials in Clash With Investors
Replies
0
Views
1K
anonymous
Axios: Promising new Alzheimer's drugs present patients with tough choices
Replies
3
Views
1K
anonymous
ICER on Leqembi
Replies
18
Views
4K
anonymous
The benefit is questionable. The danger is real.
Replies
8
Views
3K
anonymous
ALS drug
Replies
2
Views
1K
anonymous
Clinical trial participant’s autopsy and brain exam stoke Alzheimer’s drug fears | Science | AAAS
Replies
1
Views
954
anonymous
On the Verge of Full FDA Approval, New Details About Leqembi Death | Being Patient
Replies
1
Views
1K
anonymous
Struggling Biogen paid CEOs Chris Viehbacher $30.5M and Michel Vountatos $26.6M in 2022
Replies
5
Views
2K
anonymous
FiercePharma: Biogen's Alzheimer's disease sales are negative as Aduhelm fallout lingers
Replies
2
Views
1K
anonymous
Axios: New Alzheimer's drug doesn't show net benefit, report finds
Replies
2
Views
1K
anonymous
New EVP of Corporate Development
Replies
3
Views
2K
anonymous
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs: A Systematic Review and Meta-analysis
Replies
9
Views
2K
anonymous
Viehbacher...Really?
Replies
70
Views
20K
anonymous
Top Bottom
Back
Post thread